Aviado · Research
Longevity Daily
Sunday, August 9, 2026
Listen
Today's Brief
Today's strongest stories share a common thread: the science of aging is moving from theoretical to actionable, faster than most people realize. The must-read argues that nearly half of all dementia cases are already preventable — and that GLP-1 therapies have fundamentally changed the prevention calculus. A landmark Nature study rehabilitates the long-dismissed thymus as a key longevity biomarker, while the first-in-human epigenetic reprogramming trial quietly entered Phase 1. Aviado Research's latest analysis and a pointed look at the FDA's supplement oversight gaps round out a dense and consequential issue.
10 stories1 peer-reviewed1 trials1 Aviado original
Cognitive Health & Neuroprotection
Dementia Is a Preventable Disease — And We Already Have the Tools to Act
Research now estimates that up to 45% of all dementia cases could be prevented by addressing key modifiable risk factors — including weight, blood pressure, hearing loss, and social isolation. The arrival of GLP-1 weight-loss therapies has dramatically changed the calculus, making it easier than ever to tackle one of the biggest drivers of cognitive decline. If you or someone you love is worried about dementia, this is the prevention framework worth understanding — and acting on.
Read more →Your Aging Gut May Be Quietly Undermining Your Brain's Most Critical Defense
Your gut microbiome doesn't just affect digestion — age-related shifts in bacterial communities may directly compromise the blood-brain barrier, the brain's primary defense against inflammation and toxins. A new review in FEBS Letters synthesizes mounting evidence that the loss of beneficial short-chain fatty acid producers is linked to increased neurovascular vulnerability in older adults. Importantly, no human trial has yet proven that probiotic or dietary interventions can reverse BBB impairment — but the mechanistic case for acting on gut health is building fast.
Read more →Supplements & Compounds
MK-4 vs. MK-7: The Vitamin K2 Form You're Taking Actually Matters
Not all vitamin K2 is created equal — and the MK-4 vs. MK-7 debate has real implications for anyone supplementing for cardiovascular or bone health. This formulator's FAQ breaks down key differences in half-life, bioavailability, and the specific evidence base for each form, including a 2025 case study on MK-7 in kidney disease patients with calciphylaxis. If you're stacking K2 with D3, knowing which form you're taking matters more than most supplement labels let on.
Read more →AREDS3 Launches with B Vitamins and 2× the Lutein — But the Evidence Trail Has Gaps
Bausch + Lomb has launched PreserVision AREDS3, upgrading the eye-health staple with B vitamins and roughly 2× the lutein/zeaxanthin exposure of the original AREDS2 softgel. The evidence supporting the B-vitamin addition comes from a 2025 narrative review and select RCT signals — not a dedicated AREDS3 outcome trial — and the manufacturer acknowledges clinical outcome relevance remains unproven. If you or a family member takes AREDS2 for macular degeneration risk, this warrants a conversation with your ophthalmologist before switching.
Read more →Research & Papers
The Forgotten Organ Behind Your Breastbone Could Predict How Long You Live
The thymus — that small organ behind your breastbone that most textbooks dismiss as irrelevant after puberty — may be a key predictor of how long and how well you live, according to a new Nature study. Researchers found that people with healthier thymus function had meaningfully lower risks of death, lung cancer, and cardiovascular disease. This adds to growing evidence that immune system aging ("immunosenescence") is a central driver of longevity, not merely a side effect of it.
Read more →AI-Guided Gene Editing Reverses 80-Year-Old Skin Cells to an Embryonic State
Scientists have used AI-guided gene editing to reprogram 80-year-old skin cells to an embryonic-like state — one of the most dramatic demonstrations of cellular age reversal to date. The approach targets the specific transcription factors needed to reset a cell's epigenetic clock without the full safety risks of traditional Yamanaka factor reprogramming. This remains early-stage research, but it's part of a fast-moving wave of reprogramming science now inching toward clinical application.
Read more →Aviado Research: Cutting Through the Noise on Longevity Interventions
Aviado Research's latest deep-dive examines the current evidence landscape for longevity interventions, grading what the science actually supports versus what remains speculative. As the field accelerates from animal models into human trials, rigorous independent analysis is increasingly valuable for consumers and clinicians navigating supplement stacks and emerging protocols.
Read the full Aviado analysis →Lifestyle & Nutrition
The Case for Eating Less Protein Than You Think — What the Longevity Science Actually Says
The case for reducing protein intake as a longevity strategy is stronger than most health-optimizers realize, and Fight Aging!'s thorough evidence review explains why. Animal studies robustly show that lower protein availability triggers beneficial cellular maintenance pathways — the same mechanisms activated by fasting and caloric restriction — and human data is increasingly supportive. The nuance: "protein" on a food label doesn't perfectly reflect essential amino acid availability, so optimizing intake requires more sophistication than simply cutting back.
Read more →Industry & Policy
First-in-Human Epigenetic Reprogramming Trial Clears the Runway
ER-100 — a therapeutic designed to reverse cellular aging via epigenetic reprogramming — has entered a first-in-human Phase 1 clinical trial, targeting patients with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. If the safety profile holds, this trial could represent the first validated proof-of-concept for epigenetic reprogramming as a regulated human therapeutic. Earlier animal studies on vision restoration provided the preclinical rationale for this landmark step into the clinic.
Read more →Supplements Still Don't Need to Prove They Work Before Hitting Shelves — and a New Bill Won't Change That
A pending Congressional bill on dietary supplement regulation would leave intact the current system under which manufacturers are not required to demonstrate effectiveness before marketing their products. The FDA regulates supplements more like foods than drugs, meaning the burden of proving harm falls on regulators after the fact — not on manufacturers up front. For anyone spending money on longevity supplements, this makes independent evidence review more important than ever.
Read more →